New Implant Features Proven Active Ingredients, Formulated Specifically for Heifers
MADISON, N.J., February 12, 2018 — Merck Animal Health, known as MSD Animal Health outside the United States and Canada, today announced the expansion of its portfolio of cattle implants with the introduction of REVALOR®-XH (trenbolone acetate and estradiol). REVALOR-XH features the same active ingredients as REVALOR-XS — the leading cattle industry implant — but is formulated specifically for use in feedyard heifers.
“REVALOR-XH begins to work immediately and provides the same strong finish that customers have come to expect from REVALOR-XS. It also provides the same level of convenience with the second dose going to work 70 to 80 days later, eliminating the need to re-process the cattle,” says Marshall Streeter, Ph.D., technical services specialist with Merck Animal Health. “With the addition of REVALOR-XH, feedyards now have a heifer implant strategy to improve performance, maintain feed intake and reduce stress, across a wide variety of feeding and marketing conditions.”
Performance-based implants, such as REVALOR-XH, provide marketing flexibility, while maintaining excellent feedyard performance and improving margin. Additionally, REVALOR-XH and REVALOR-XS help producers who may struggle with re-implanting challenges, such as weather events that delay re-implanting or result in increased maintenance costs and stressor exposure.
“Every time cattle are removed from their pen, moved across the feedyard, walked through the chute and returned to their original pen, the entire feeding operation experiences increased resource allocation demands and greater risk of injury to workers and cattle,” says Dr. Streeter. “When we disrupt cattle from their daily routine due to the re-implanting process, we may negatively affect performance and health, Revalor-XH helps to limit those disruptions.”
For more information on Revalor-XH, please contact your Merck Animal Health representative.
Important Safety Information:
A withdrawal period has not been established for Revalor in pre-ruminating calves. Do not use in calves to be processed for veal. For complete information, refer to product label.
About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov.).